EGFR and non-small cell lung carcinoma: In a significant clinical trial involving patients with advanced EGFR-mutated stage III NSCLC, the drug osimertinib markedly prolonged PFS compared to a placebo-controlled trial, with patients living without disease progression for an average of 39.1 months vs. just 5.6 months.